PNC
ELOX

Point Nemo Capital’s Eloxx Pharmaceuticals ELOX Stock Holding History

Point Nemo Capital’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Buy
+1
New +$13 ﹤0.01% 182

Other funds holding ELOX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SGM
Seven Grand Managers Bronxville, New York $2.48B AUM 65.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Point Nemo Capital's ELOX Position: Q2 2026 in Review

Point Nemo Capital opened a new position in Eloxx Pharmaceuticals (ELOX) in Q2 2026: 1 share worth $14. The stake represents ﹤0.01% of the portfolio and ranks #182 among its holdings.

20 funds tracked by Wall St. Rank hold ELOX as of Q2 2026.

  • Point Nemo Capital held 1 share of Eloxx Pharmaceuticals worth $14 as of Q2 2026.
  • Eloxx Pharmaceuticals was a new Point Nemo Capital position in Q2 2026.
  • Eloxx Pharmaceuticals made up ﹤0.01% of Point Nemo Capital's portfolio in Q2 2026, its #182 holding.
  • 20 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals as of Q2 2026.

Based on Point Nemo Capital's 13F filing for Q2 2026, filed 7 Aug 2026.